Nocturnal recovery of gastric acid secretion with twice-daily dosing of proton pump inhibitors.
about
Refractory chronic cough due to gastroesophageal reflux: Definition, mechanism and management.Globus pharyngeus: a review of its etiology, diagnosis and treatmentA stepwise protocol for the treatment of refractory gastroesophageal reflux-induced chronic cough.Time esophageal pH < 4 overestimates the prevalence of pathologic esophageal reflux in subjects with gastroesophageal reflux disease treated with proton pump inhibitorsReflux laryngitis: pathophysiology, diagnosis, and management.Gastroesophageal reflux disease in asthma: effects of medical and surgical antireflux therapy on asthma control.Columnar mucosa and intestinal metaplasia of the esophagus: fifty years of controversy.Controlling on-demand gastric acidity in obese subjects: a randomized, controlled trial comparing a single dose of 20 mg rabeprazole and 20 mg omeprazoleTenatoprazole, a novel proton pump inhibitor with a prolonged plasma half-life: effects on intragastric pH and comparison with esomeprazole in healthy volunteers.Barrett's esophagus and the increasing role of endoluminal therapy.CYP2C19 pharmacogenomics associated with therapy of Helicobacter pylori infection and gastro-esophageal reflux diseases with a proton pump inhibitor.Pharmacogenomics of proton pump inhibitors.Review article: diagnosis and management of night-time reflux.Barrett's oesophagus: the new endoscopic modalities have a future.Nocturnal acid breakthrough - approach to management.Risk of community-acquired pneumonia in patients with a diagnosis of pernicious anemia: a population-based retrospective cohort study.Effect of a single oral dose of rabeprazole on nocturnal acid breakthrough and nocturnal alkaline amplitudeGastric reacidification with betaine HCl in healthy volunteers with rabeprazole-induced hypochlorhydria.Effects of rikkunshito on quality of life in patients with gastroesophageal reflux disease refractory to proton pump inhibitor therapy.Esophageal Acidification During Nocturnal Acid-breakthrough with Ilaprazole Versus Omeprazole in Gastroesophageal Reflux Disease.Acid peptic diseases: pharmacological approach to treatment.The effects of baclofen for the treatment of gastroesophageal reflux disease: a meta-analysis of randomized controlled trialsA review of medical therapy for proton pump inhibitor nonresponsive gastroesophageal reflux disease.A Meta-Analysis and Systematic Review of the Efficacy of Twice Daily PPIs versus Once Daily for Treatment of Gastroesophageal Reflux Disease.Can Nocturnal Acid-breakthrough Be Reduced by Long-acting Proton Pump Inhibitors?New method for long-term monitoring of intragastric pH.Bedtime H2 blockers improve nocturnal gastric acid control in GERD patients on proton pump inhibitors.Integrated acidity and rabeprazole pharmacology.Dose-dependent control of intragastric pH by pantoprazole, 10, 20 or 40 mg, in healthy volunteers.Comparison of lansoprazole and famotidine for gastric acid inhibition during the daytime and night-time in different CYP2C19 genotype groups.An evaluation of the clinical implications of acid breakthrough in patients on proton pump inhibitor therapy.The effects of nocturnal acid breakthrough on Helicobacter pylori eradication.Nocturnal acid breakthrough: clinical significance and correlation with esophageal acid exposure.The efficacy of omeprazole twice daily with supplemental H2 blockade at bedtime in the suppression of nocturnal oesophageal and gastric acidity.Effect of omeprazole 10 mg on intragastric pH in three different CYP2C19 genotypes, compared with omeprazole 20 mg and lafutidine 20 mg, a new H2-receptor antagonist.Rabeprazole 10 mg twice daily is superior to 20 mg once daily for night-time gastric acid suppression.The acidity index: a simple approach to the measurement of gastric acidity.Effect of splitting the dose of esomeprazole on gastric acidity and nocturnal acid breakthrough.Different patterns of oesophageal acid exposure distinguish complicated reflux disease from either erosive reflux oesophagitis or non-erosive reflux disease.Efficacy and safety of twice-daily rabeprazole maintenance therapy for patients with reflux esophagitis refractory to standard once-daily proton pump inhibitor: the Japan-based EXTEND study.
P2860
Q26785656-AB95908B-65C4-4E48-BD8A-C746CB6D2A82Q27006482-03B197FD-B9F3-4C2C-8D45-3106FC6B99EEQ30390631-8A160B61-33F5-4E8B-82AE-214BDC74F888Q33337244-E15868B5-4EDF-4048-A714-6EA582D92365Q33751634-302CE9FE-D6A9-4826-8B49-E6AB3F216DA2Q33837708-291139BC-DC17-47D2-BEC0-B2F9B7F4F395Q33861398-CEF50148-A582-41A5-86C3-09B2FA363298Q33946261-370E2676-D90D-4528-9D1B-1C608ADBB702Q34306075-96A3AFD5-CD72-4CE6-8C76-928B982672FCQ34408906-062EA81A-8708-4AD0-92EE-674C44D05EE1Q34583603-403DD8D5-7111-43E5-9541-3B91772CEE2EQ35689146-629BB540-A8EF-4307-838D-E11274A73AAEQ35939808-EA5DDD35-FA6E-49AA-92E7-3911133C4966Q36041664-0A3D2E28-119F-4ADB-A7DD-C9F5E6356B54Q36073758-9500FA2E-9F3C-4624-BF1C-E16DB9C9F925Q36101677-4B23B159-28B1-4FA6-9440-C7505793940EQ36308910-67E0F34E-38BF-42D3-BF37-A7CCC3913576Q37624513-39F81C20-0C8F-4785-8CA2-D9FEA1108C25Q37726472-8A4EDDC6-2DA3-45E6-960B-AC174D534B0FQ37740015-AFD7CB14-9257-42E9-B432-A3AB446D1AB6Q37913063-AAE586DD-69EC-46AA-81DD-2DD12C7F0327Q38267393-9D428B69-A60F-4107-9811-3FB109A3BF0DQ38599606-9F5D3EDB-08F7-4CC4-82DF-DAD016B7AAB8Q41623112-673CFC1D-39A6-4FDC-A4A3-1DCEBE9F5320Q42365931-286B6476-DA93-4BE9-9A23-51646ED410B8Q42954885-92E8B91F-1C70-41A5-BC66-DA502AC2AA0FQ43734554-1CC68CA1-F47B-4D61-938A-95768F052B94Q43904271-8483CCF7-B8A3-425E-AD11-1013ED39E697Q43944832-D4FEB431-18FC-4D49-B3FD-00BACDCB3F04Q43944835-EF4FC4E8-D61A-413C-8692-2C9F935E1ECBQ44080551-076CAB57-BF8E-4C21-8112-F745F72CBB28Q44251109-D6868D35-5585-4655-8F1D-7B85BA335CAAQ44371344-DEBB10F7-6604-4AFB-B099-0622159B80ADQ44488917-419FF95E-36FB-4287-B000-229E09B8EEC5Q44678734-334EDA4B-78D6-4D79-9F74-C564894C07A8Q44700487-D15C2DA6-B297-42C5-B1F3-9FD3269EB350Q44761473-F81D1846-E812-4232-834E-E3EA2926D0B6Q44895190-D27A1BFF-6BDB-43A9-86FB-BF91E1F14E5CQ47344490-9431459E-9617-4A3E-8638-44150AE881A7Q49502751-090F8E83-306C-4511-89BC-CC4A0B5D04A8
P2860
Nocturnal recovery of gastric acid secretion with twice-daily dosing of proton pump inhibitors.
description
1998 nî lūn-bûn
@nan
1998 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
1998 թվականի մայիսին հրատարակված գիտական հոդված
@hy
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
name
Nocturnal recovery of gastric ...... ing of proton pump inhibitors.
@ast
Nocturnal recovery of gastric ...... ing of proton pump inhibitors.
@en
Nocturnal recovery of gastric ...... ing of proton pump inhibitors.
@nl
type
label
Nocturnal recovery of gastric ...... ing of proton pump inhibitors.
@ast
Nocturnal recovery of gastric ...... ing of proton pump inhibitors.
@en
Nocturnal recovery of gastric ...... ing of proton pump inhibitors.
@nl
prefLabel
Nocturnal recovery of gastric ...... ing of proton pump inhibitors.
@ast
Nocturnal recovery of gastric ...... ing of proton pump inhibitors.
@en
Nocturnal recovery of gastric ...... ing of proton pump inhibitors.
@nl
P2093
P1476
Nocturnal recovery of gastric ...... ing of proton pump inhibitors.
@en
P2093
P304
P356
10.1016/S0002-9270(98)00101-4
P407
P577
1998-05-01T00:00:00Z